F-1: Aptorum Merges with DiamiR, Faces Going Concern & Nasdaq Delisting Risks

Aptorum Group Limited is pursuing a strategic merger with DiamiR Biosciences Corp. to enhance its R&D pipeline, despite ongoing financial challenges and a recent capital raise.

Summary

• Aptorum Group Limited is undertaking a strategic merger with DiamiR Biosciences Corp., a molecular diagnostic company, with DiamiR becoming a wholly-owned subsidiary.
• Post-merger, DiamiR's existing stockholders will own approximately 70% and Aptorum's existing shareholders will own approximately 30% of the combined company.
• Aptorum recently raised approximately $2 million in gross proceeds from the sale of 1,000,000 Class A Ordinary Shares and warrants to purchase 2,000,000 shares, and $3,070,000 from a registered direct offering of 1,535,000 Class A Ordinary Shares.
• Aptorum reported a net loss of $4,157,737 for the year ended December 31, 2024, and an accumulated deficit of $72,429,528 as of that date.
• DiamiR reported net losses of $743,235 for the year ended May 31, 2025, and an accumulated deficit of $6,106,271 as of August 31, 2025.
• Both Aptorum and DiamiR's auditors have expressed substantial doubt about their respective abilities to continue as a going concern.
• Aptorum's lead drug candidates, ALS-4 (bacterial infections) and SACT-1 (neuroblastoma), have completed Phase 1 clinical trials and are progressing towards Phase 2/1-2 trials, contingent on funding and partnerships.
• DiamiR's lead diagnostic product, CogniMIR, for early detection of mild cognitive impairment and Alzheimer's disease, is analytically validated and plans for a clinical validation study in 2H 2026.
• DiamiR recently discovered a cyber-attack, the full details and implications of which are still being uncovered.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to severe financial distress for both companies, including recurring net losses, significant accumulated deficits, and explicit going concern warnings from auditors. While the merger offers strategic potential and R&D progress is noted, these positives are overshadowed by immediate liquidity concerns, regulatory compliance issues (Nasdaq delisting threat), and operational risks like the cyber-attack. The significant ownership dilution for existing Aptorum shareholders in the merger, coupled with the concentration of voting power in the CEO, further diminishes the attractiveness for new investors. The cumulative negatives far outweigh the potential long-term R&D benefits, making the stock a strong sell.

Positives

• The strategic merger with DiamiR Biosciences is expected to enhance Aptorum's R&D pipeline, particularly in neurodegenerative diseases and cancer diagnostics, aligning with a broader therapeutic focus.
• DiamiR's proprietary technology, based on quantitative analysis of circulating organ-enriched microRNAs, is protected by over 50 issued patents, providing a strong IP foundation for the combined entity.
• DiamiR's CogniMIR panel for MCI and AD risk assessment is analytically validated, with plans for a clinical validation study in 2H 2026, addressing a significant unmet medical need in an aging population.
• Aptorum's lead drug candidates, ALS-4 and SACT-1, have successfully completed Phase 1 clinical trials and received positive feedback from the US FDA on their development strategies, indicating progress towards later-stage trials.
• SACT-1 has been granted Orphan Drug Designation by the US FDA, which can provide benefits like fee reductions and market exclusivity.
• DiamiR has a CLIA-certified, CAP-accredited laboratory, which is crucial for developing and commercializing lab-developed tests (LDTs).
• DiamiR has secured over $9.7 million in non-dilutive grant funding from government agencies and disease foundations since its inception, demonstrating external validation of its research.
• The recent court ruling striking down the FDA's final rule to regulate LDTs as medical devices reduces immediate regulatory burdens and costs for DiamiR's LDT-focused business model.

Negatives

• Both Aptorum and DiamiR's auditors have expressed substantial doubt about their respective abilities to continue as a going concern due to recurring net losses and limited cash reserves.
• Aptorum reported a net loss of $4,157,737 for the year ended December 31, 2024, and an accumulated deficit of $72,429,528, indicating significant financial instability.
• DiamiR has incurred net losses in each year since its inception, including $743,235 for the year ended May 31, 2025, and has an accumulated deficit of $6,106,271.
• Aptorum's ability to advance ALS-4 Phase 2 and SACT-1 Phase 1/2 trials is contingent upon securing appropriate collaborative partnerships and adequate funding resources, which are not guaranteed.
• DiamiR's grant funding, a primary source of revenue, was exhausted by May 31, 2025, and future grant revenues are expected to decrease significantly or cease.
• DiamiR relies on sole suppliers for some critical materials used in its tests and services, posing a supply chain risk if replacements are not found in a timely manner.
• Aptorum is party to a lawsuit alleging RICO violations, fraud, and breach of fiduciary duty, which could result in substantial costs and divert management attention.
• Aptorum's CEO, Ian Huen, controls approximately 87% of the company's voting power due to a dual-class share structure, limiting the influence of other shareholders.
• DiamiR recently discovered a cyber-attack, the full details and implications of which are still being uncovered, posing risks of data breaches, IP theft, and reputational damage.
• Aptorum's Class A Ordinary Shares are currently below Nasdaq's minimum bid price requirement, risking delisting if compliance is not regained by October 14, 2025.

Risks

• If the Merger Agreement with DiamiR is not consummated, Aptorum's share price could decline, and it may incur significant expenses, be unable to pursue business opportunities, and face potential delisting.
• DiamiR has never generated revenue from product sales and all of its product candidates are in the pre-commercial stage, making it difficult to evaluate its future success and potential profitability.
• The Combined Company will need to raise additional capital, which may cause dilution to stockholders or restrict operations through debt covenants.
• Anti-takeover provisions in the Proposed Charter and Bylaws and under Delaware law could make an acquisition of the Combined Company more difficult, potentially preventing beneficial transactions for stockholders.
• Aptorum's preclinical development is a long, expensive, and uncertain process, with a high failure rate, and management may terminate programs without public announcement.
• Difficulties in enrolling patients in clinical trials could delay or adversely affect Aptorum's clinical development activities.
• Aptorum's drug candidates may cause undesirable adverse events or have other properties that could delay or prevent regulatory approval, limit commercial profile, or result in negative consequences post-approval.
• Aptorum's IP portfolio includes pending patent applications that may not be issued, and issued patents may be challenged, limiting protection against competitors.
• Aptorum may be involved in costly and time-consuming lawsuits to protect or enforce its IP, or be sued for infringing others' IP rights.
• Aptorum's reliance on unrelated parties for R&D, manufacturing, and clinical trials exposes it to risks if these parties fail to meet contractual duties or deadlines.
• Aptorum's operations in Hong Kong are subject to political and legal risks, including potential intervention by the PRC government and uncertainties in the legal system.
• Aptorum may be classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. Holders.
• DiamiR's business model is heavily reliant on the adoption of its products by researchers, clinicians, and healthcare administrators, and slow adoption could harm future sales growth.
• DiamiR relies on a sole supplier for some critical materials, posing a risk of interruption in test processing and higher costs if replacements are not found.
• DiamiR's information technology systems or data, or those of its service providers, could be subject to cyber-attacks or other security incidents, leading to data breaches, IP theft, and reputational damage.
• DiamiR's laboratory could become inoperable due to natural disasters or other events, halting testing and harming its business.
• DiamiR's ability to commercialize products depends on adequate reimbursement from third-party payers, which is uncertain and subject to cost-containment measures.

Future Outlook

Aptorum expects its R&D expenses to significantly increase as it advances and expands its drug candidates. The timing and scope of advancing ALS-4 Phase 2 and SACT-1 Phase 1/2 trials are contingent upon securing collaborative partnerships and adequate funding. DiamiR anticipates continued operating losses and expects expenses to increase substantially due to continued development of CogniMIR, pipeline projects, and planned commercialization efforts. DiamiR does not expect CogniMIR to be commercially available with reimbursement in place before fiscal 2027, if at all, and will require substantial additional capital. The combined company will need to raise additional capital sooner than currently planned, which may cause dilution or restrict operations.

Management Comments

• Aptorum's management believes that by merging with DiamiR, it can achieve greater shareholder value and have a stronger growth trajectory.
• Aptorum's board of directors considered the potential for DiamiR's product candidates in brain health, cancer, and inflammatory diseases to create long-term value for stockholders.
• Aptorum's board also considered the potential synergies when combining its SACT-1 therapeutic program with DiamiR's technology, and the enhanced ability to raise capital with a broader product portfolio.
• Aptorum's management believes that the Merger is more favorable to its stockholders than other strategic options, which would likely be a delisting of its Class A ordinary shares from Nasdaq if the Merger is not consummated.
• DiamiR's management believes its core miRNA technology is robust and applicable to early detection of disease pathology in different organs, enabling a novel approach to screening.
• DiamiR's management believes that its innovative platform technology may prove to have utility in identification of pre-symptomatic, MCI and early dementia patients, opening up a significant opportunity for a pharma services business.
• DiamiR's management team has experience with, and understands the process, and will focus its efforts to gain insurance coverage in a timely manner for its diagnostic products.

Industry Context

The biopharmaceutical and molecular diagnostics industries are highly competitive and characterized by rapid technological change. The market for neurodegenerative disease diagnostics, particularly Alzheimer's, is growing rapidly due to increased lifespan and significant unmet needs, with substantial NIH funding increases. Recent FDA approvals for Alzheimer's treatments (lecanemab, donanemab) validate the importance of early detection and patient stratification, which aligns with DiamiR's focus on minimally invasive biomarkers. The regulatory landscape for lab-developed tests (LDTs) is evolving, with a recent court ruling temporarily easing FDA oversight, potentially benefiting DiamiR's strategy. However, the industry faces high R&D costs, long development timelines, and significant competition from larger, more established companies.

Comparison to Industry Standards

• DiamiR's CogniMIR test aims to differentiate MCI and AD with up to 0.95 accuracy, and predict progression 1-5 years prior to diagnosis with 0.84 accuracy, which compares favorably to the general challenges in early AD detection.
• DiamiR's technology for differentiating AD from other neurodegenerative diseases (PD/FTD/ALS) achieved accuracies ranging from 0.83 to 0.90 (AUCs: 0.93 to 0.96), indicating strong performance in a complex diagnostic area.
• The cost of bringing a repurposed drug like SACT-1 to market is estimated at around $300 million, significantly lower than the average $2.6 billion for a new drug, aligning with industry trends for cost-efficient drug development.
• DiamiR's approach of combining miRNA with blood protein markers for patient stratification and monitoring in clinical trials is complementary, and potentially synergistic, to existing diagnostic platforms like imaging and traditional blood protein biomarkers (e.g., Roche's Elecsys pTau181, Fujirebio's Lumipulse G pTau 217/Aβ 1-42 Plasma Ratio), potentially offering a more comprehensive solution.
• DiamiR's CLIA/CAP-certified lab operations and adherence to quality standards are in line with industry best practices for diagnostic testing, as evidenced by successful renewals of its licenses.

Management Changes

Corporate Governance

Legal Proceedings

• Aptorum is a party to a lawsuit filed on September 3, 2024, by Karen Cheung in the Supreme Court of the State of New York, alleging violations of the federal Racketeer Influenced and Corrupt Organizations Act (RICO), conspiracy to violate RICO, fraud, aiding and abetting breach of fiduciary duty, unjust enrichment, and civil conspiracy.
• The lawsuit was removed to the U.S. District Court for the Southern District of New York on December 27, 2024.
• Plaintiff filed a First Amended Complaint on June 2, 2025, and Aptorum filed its opening brief on a motion to dismiss on July 18, 2025, with the plaintiff's opposition filed on September 5, 2025.
• Aptorum believes the plaintiff's claims have no merit and will vigorously defend against them; the costs and expenses of defending the lawsuit are currently unknown.

Related Party Transactions

• Aptorum Therapeutics Limited (Aptorum subsidiary) has a line of credit up to $12,000,000 with Aeneas Group Limited, extended to August 12, 2025, at 8% interest per annum. No drawdowns as of the filing date.
• Aptorum Therapeutics Limited also had a line of credit up to $3,000,000 with Jurchen Investment Corporation (Aptorum's largest shareholder), which matured.
• Aptorum has a secured convertible note of $3,000,000 (Sep 2023 Notes) with Jurchen Investment Corporation, bearing 6% interest per annum and convertible at $2.42 per share. The term was extended for 12 months on September 11, 2025, with Jurchen gaining sole discretion to convert upon three days' notice.
• Aptorum has a line of credit facility with Libra Sciences Limited (a VIE where Aptorum holds 97.27% economic interest but is not the primary beneficiary) for up to $1 million, extended for 3 years, with $0.5 million outstanding as of the filing date. An allowance for credit loss of $0.5 million was recognized for 2023 due to unrecoverability.
• DiamiR has outstanding convertible notes totaling $957,662 as of May 31, 2025, to its founders, Samuil R. Umansky and Kira Sheinerman, bearing 4% interest, maturing December 31, 2026.
• Kira Sheinerman (DiamiR co-founder and Executive Director) loaned DiamiR an additional $100,000 in April 2025 and $150,000 in June 2025 through amendments to her convertible note.
• Kira Sheinerman is a managing director of H.C. Wainwright & Co., LLC, which is DiamiR's exclusive financial advisor for the merger and will receive warrants as compensation upon merger consummation.

Stakeholder Impact

• Shareholders of both Aptorum and DiamiR will experience significant ownership dilution in the combined company, with DiamiR stockholders owning approximately 70% and Aptorum shareholders 30%.
• Aptorum's Class A Ordinary Shareholders face potential delisting from Nasdaq if the minimum bid price requirement is not met, which would severely impact liquidity and investment value.
• Investors face substantial risk due to the 'going concern' warnings for both companies, indicating a high probability of needing further capital raises, which could lead to additional dilution.
• Employees of both companies may experience uncertainty regarding their future roles within the combined company, potentially affecting retention of key personnel.
• Customers and partners of DiamiR's diagnostic services may benefit from enhanced R&D capabilities and a broader product portfolio in the combined entity, but could also be impacted by operational disruptions or financial instability.
• Creditors of both companies face risks related to the companies' financial distress and the need for additional financing, which could affect the repayment of existing debts.
• The dual-class voting structure of Aptorum, with CEO Ian Huen controlling 87% of voting power, means other shareholders have limited influence over corporate matters, and this structure will persist in the combined entity through preferred stock.

Next Steps

• Aptorum is proceeding towards IND submission for ALS-4 to initiate a Phase 2 clinical study, contingent on securing collaborative partnerships and adequate funding.
• Aptorum is seeking strategic collaborators to provide financial support and clinical expertise to advance ALS-4 Phase 2 and SACT-1 Phase 1/2 clinical trials.
• DiamiR plans to initiate a clinical validation study for CogniMIR in 2H 2026 to demonstrate diagnostic performance and satisfy CLIA and CAP requirements.
• DiamiR is expanding its menu to offer Pharma testing services to companies developing therapeutic and treatment products, which could be used for screening, patient stratification, or disease/treatment monitoring.
• DiamiR plans to introduce automation and robots into its lab operations to increase capacity, reduce turn-around-time, improve efficiency, and lower COGS.
• DiamiR plans to develop a second-generation software with Machine Learning and AI capabilities to support its LDTs and optimize its classifier.
• DiamiR plans to offer both sequencing services (MECP2 gene) and its proprietary miRNA panel for Rett syndrome diagnostic solutions.
• DiamiR plans to implement a robust commercial strategy aimed at securing coverage and contracting with Medicare and private payors for its diagnostic tests.
• Aptorum will domesticate as a Delaware corporation prior to the DiamiR Merger closing.
• The DiamiR Merger is subject to shareholder approval, Nasdaq review of the listing application, and the conversion of all outstanding convertible debt of both companies.
• Aptorum must maintain an aggregate of unrestricted cash and cash equivalents of not less than $2,260,000 and working capital of not less than $1,644,000 at the closing date of the merger.

Key Dates

Recommendation

The filing presents a highly concerning financial picture for both Aptorum and DiamiR, with both companies receiving 'going concern' warnings from their auditors due to recurring net losses and insufficient capital. Aptorum faces an immediate threat of Nasdaq delisting due to its low share price. While the merger offers a strategic rationale for pipeline expansion, the severe financial instability, the need for substantial future capital raises (which will cause further dilution), and the operational risks (including a cyber-attack on DiamiR and ongoing litigation for Aptorum) create an extremely high-risk investment profile. The significant ownership dilution for existing Aptorum shareholders in the merger, coupled with the concentration of voting power in the CEO, further diminishes the attractiveness for new investors. The cumulative negatives far outweigh the potential long-term R&D benefits, making the stock a strong sell.

Keywords

Biopharmaceutical, Molecular Diagnostics, Merger, SEC Filing, Clinical Trials, Drug Development, Neurodegenerative Diseases, Alzheimer's Disease, Cancer Diagnostics, Orphan Drug, Warrants, Capital Raise, Going Concern, Intellectual Property, Regulatory Approval, Hong Kong, China Risk, Cybersecurity, Biomarkers, MicroRNA